Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer

Author(s): Georgios Ioannis Papageorgiou*, Nikolaos Skouteris, Aikaterini Kosma, Athina Markouizou and Nikolaos Charalampakis

Volume 18, Issue 2, 2023

Published on: 12 April, 2023

Page: [146 - 155] Pages: 10

DOI: 10.2174/1574887118666230412112136

Price: $65

Abstract

Background: Metastatic castrate-resistant prostate cancer (mCRPC) is a challenging disease, especially in heavily pretreated patients. Androgen pathway inhibitors have contributed to a notable improvement in the overall survival and quality of life in patients with mCRPC during the last decade. Still, a considerable percentage of patients are unable to draw benefits from this drug category and are deprived of a treatment that offers limited toxicity and preserves a good quality of life. The mechanisms leading to this pre-existing or acquired resistance, as well as the possible strategies to overcome this resistance have been put at the center of scientists’ attention.

Case Presentation: With the present report we present the case of a 70-year-old patient with mCRPC, who was apparently an enzalutamide non-responder, but a multimodal approach with enzalutamide continuation and irradiation to his symptomatic oligoprogressive disease converted him to a responder with clinical, biochemical and imaging response; furthermore, we discuss the existing data providing evidence for the use of metastasis-directed therapy in combination with androgen pathway inhibitors in order to overcome drug resistance in patients with oligoprogressive disease.

Conclusion: A considerable proportion of patients with oligometastatic or oligoprogressive prostate cancer who seem not to respond to androgen pathway inhibitors, such as enzalutamide, due to preexisting or acquired resistance, could benefit from MDT with a multimodal treatment approach. This strategy allows androgen pathway inhibitor continuation beyond biochemical progression and delays the switch to next-line systemic treatment.

« Previous Next »
Graphical Abstract

[1]
Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet 2021; 398(10305): 1075-90.
[http://dx.doi.org/10.1016/S0140-6736(21)00950-8] [PMID: 34370973]
[2]
Storås AH, Fosså SD, Ursin G, Andreassen BK. Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. Prostate Cancer Prostatic Dis 26(1): 53-8.
[http://dx.doi.org/10.1038/s41391-021-00445-x] [PMID: 34493838]
[3]
Massaro M, Facondo G, Vullo G, et al. Androgen receptor targeted therapy + radiotherapy in metastatic castration resistant prostate cancer. Front Oncol 2021; 11: 695136.
[http://dx.doi.org/10.3389/fonc.2021.695136] [PMID: 34631527]
[4]
Livi L, Detti B, Francolini G, et al. Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: A review of current evidence. Tumori 2019; 105(4): 277-81.
[http://dx.doi.org/10.1177/0300891619839282] [PMID: 30905318]
[5]
Wani SQ, Dar IA, Khan T, Lone MM, Afroz F. Radiation therapy and its effects beyond the primary target: An abscopal effect. Cureus 2019; 11(2): e4100.
[http://dx.doi.org/10.7759/cureus.4100] [PMID: 31057994]
[6]
Tombal B, Stenzl A, Cella D, et al. The impact of enzalutamide on the prostate cancer patient experience: A summary review of health-related quality of life across pivotal clinical trials. Cancers 2021; 13(23): 5872.
[http://dx.doi.org/10.3390/cancers13235872] [PMID: 34884981]
[7]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[8]
Gourdin T. Recent progress in treating advanced prostate cancer. Curr Opin Oncol 2020; 32(3): 210-5.
[http://dx.doi.org/10.1097/CCO.0000000000000624] [PMID: 32209821]
[9]
Scott LJ. Enzalutamide: A review in castration-resistant prostate cancer. Drugs 2018; 78(18): 1913-24.
[http://dx.doi.org/10.1007/s40265-018-1029-9] [PMID: 30535926]
[10]
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187-97.
[http://dx.doi.org/10.1056/NEJMoa1207506] [PMID: 22894553]
[11]
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5): 424-33.
[http://dx.doi.org/10.1056/NEJMoa1405095] [PMID: 24881730]
[12]
Swami U, Sinnott JA, Haaland B, et al. Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States. Cancers 2021; 13(19): 4951.
[http://dx.doi.org/10.3390/cancers13194951] [PMID: 34638435]
[13]
Payne H, Robinson A, Rappe B, et al. A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE. Int J Cancer 2022; 150(5): 837-46.
[http://dx.doi.org/10.1002/ijc.33845] [PMID: 34648657]
[14]
Chen J, Zhang Y, Zhang X, et al. Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: A systematic review and network meta-analysis. Front Pharmacol 2022; 12: 789319.
[http://dx.doi.org/10.3389/fphar.2021.789319] [PMID: 35115934]
[15]
Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S. Enzalutamide therapy for advanced prostate cancer: Efficacy, resistance and beyond. Endocr Relat Cancer 2019; 26(1): R31-52.
[http://dx.doi.org/10.1530/ERC-18-0289] [PMID: 30382692]
[16]
Conteduca V, Crabb SJ, Scarpi E, et al. Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Mol Diagn Ther 2016; 20(3): 255-63.
[http://dx.doi.org/10.1007/s40291-016-0196-1] [PMID: 27020582]
[17]
Saad F, Sternberg CN, Efstathiou E, et al. Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: Any rise in prostate-specific antigen may require closer monitoring. Eur Urol 2020; 78(6): 847-53.
[http://dx.doi.org/10.1016/j.eururo.2020.08.025] [PMID: 33010985]
[18]
Kohrt SE, Awadallah WN, Phillips RA III, et al. Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro. Mol Cancer Ther 2021; 20(2): 398-409.
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0244] [PMID: 33298586]
[19]
Lee GT, Rosenfeld JA, Kim WT, et al. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLoS One 2019; 14(9): e0213488.
[http://dx.doi.org/10.1371/journal.pone.0213488] [PMID: 31536510]
[20]
Hsieh YT, Chiang BJ, Wu CC, Liao CH, Lin CD, Chen CH. High tumor burden predicts poor response to enzalutamide in metastatic castration-resistant prostate cancer patients. Cancers 2021; 13(16): 3966.
[http://dx.doi.org/10.3390/cancers13163966] [PMID: 34439119]
[21]
Wang Y, Chen J, Wu Z, et al. Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol 2021; 178(2): 239-61.
[http://dx.doi.org/10.1111/bph.15300] [PMID: 33150960]
[22]
Patel PH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: Treat the Whole Lawn or Weed Selectively? Clin Oncol 2019; 31(12): 824-33.
[http://dx.doi.org/10.1016/j.clon.2019.05.015] [PMID: 31182289]
[23]
Montero A, Hernando O, Cañon V, et al. Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot’em all! Rep Pract Oncol Radiother 2021; 26(4): 605-15.
[http://dx.doi.org/10.5603/RPOR.a2021.0077] [PMID: 34434577]
[24]
De Bleser E, Tran PT, Ost P. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol 2017; 27(6): 587-95.
[http://dx.doi.org/10.1097/MOU.0000000000000441] [PMID: 28816714]
[25]
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36(5): 446-53.
[http://dx.doi.org/10.1200/JCO.2017.75.4853] [PMID: 29240541]
[26]
Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial. Eur Urol 2018; 74(4): 455-62.
[http://dx.doi.org/10.1016/j.eururo.2018.06.004] [PMID: 30227924]
[27]
Franzese C, Zucali PA, Di Brina L, et al. The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Med 2018; 7(9): 4379-86.
[http://dx.doi.org/10.1002/cam4.1707] [PMID: 30073758]
[28]
Triggiani L, Alongi F, Buglione M, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 2017; 116(12): 1520-5.
[http://dx.doi.org/10.1038/bjc.2017.103] [PMID: 28449007]
[29]
Triggiani L, Mazzola R, Magrini SM, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: A multicenter study. World J Urol 2019; 37(12): 2631-7.
[http://dx.doi.org/10.1007/s00345-019-02717-7] [PMID: 30859273]
[30]
Deek MP, Taparra K, Phillips R, et al. Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol 2021; 4(3): 447-55.
[http://dx.doi.org/10.1016/j.euo.2020.05.004] [PMID: 32536574]
[31]
Onal C, Kose F, Ozyigit G, et al. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment. Prostate 2021; 81(9): 543-52.
[http://dx.doi.org/10.1002/pros.24132] [PMID: 33905131]
[32]
Sekhar KR, Wang J, Freeman ML, Kirschner AN. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway. PLoS One 2019; 14(4): e0214670.
[http://dx.doi.org/10.1371/journal.pone.0214670] [PMID: 30933998]
[33]
Barrado M, Blanco-Luquin I, Navarrete PA, et al. Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring. Rep Pract Oncol Radiother 2019; 24(2): 221-6.
[http://dx.doi.org/10.1016/j.rpor.2019.02.002] [PMID: 30858765]
[34]
Brennan V, Spektor A, Sweeney C, et al. Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for oligometastatic prostate cancer. Adv Radiat Oncol 2022; 7(1): 100808.
[http://dx.doi.org/10.1016/j.adro.2021.100808] [PMID: 35071831]
[35]
Patel P, Tunariu N, Tree A. Prevalence of oligoprogression in metastatic hormone-resistant prostate cancer patients on androgen targeted therapies: Could targeted radiotherapy improve patient outcomes? J Clin Oncol 2021; 39(6) (Suppl.): 110-0.
[http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.110]
[36]
Francolini G, Detti B, Di Cataldo V, et al. ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate. J Clin Oncol 2022; 40(6_suppl): 100-0.
[http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.100]
[37]
Obek C, Doganca T, Argun OB, Kural AR. Management of prostate cancer patients during COVID-19 pandemic. Prostate Cancer Prostatic Dis 2020; 23(3): 398-406.
[http://dx.doi.org/10.1038/s41391-020-0258-7] [PMID: 32690870]
[38]
Tsamakis K, Gavriatopoulou M, Schizas D, et al. Oncology during the COVID 19 pandemic: Challenges, dilemmas and the psychosocial impact on cancer patients. (Review). Oncol Lett 2020; 20(1): 441-7.
[http://dx.doi.org/10.3892/ol.2020.11599] [PMID: 32565968]
[39]
Armstrong AJ, Al-Adhami M, Lin P, et al. Association between new unconfirmed bone lesions and outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide. JAMA Oncol 2020; 6(2): 217-25.
[http://dx.doi.org/10.1001/jamaoncol.2019.4636] [PMID: 31830211]
[40]
Zschaeck S, Lohaus F, Beck M, et al. PSMA-PET based radiotherapy: A review of initial experiences, survey on current practice and future perspectives. Radiat Oncol 2018; 13(1): 90.
[http://dx.doi.org/10.1186/s13014-018-1047-5] [PMID: 29751842]
[41]
Lohaus F, Zöphel K, Löck S, et al. Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease? Eur Urol 2019; 75(4): 548-51.
[http://dx.doi.org/10.1016/j.eururo.2018.11.050] [PMID: 30578119]
[42]
Mazzola R, Francolini G, Triggiani L, et al. Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer 2021; 19(3): 230-6.
[http://dx.doi.org/10.1016/j.clgc.2020.08.002] [PMID: 32863189]
[43]
Henkenberens C, Derlin T, Bengel F, et al. Efficacy of PSMA PET-guided radiotherapy for oligometastatic castrate-resistant prostate cancer. Front Oncol 2021; 11: 664225.
[http://dx.doi.org/10.3389/fonc.2021.664225] [PMID: 33954116]
[44]
Lengana T, Lawal IO, Boshomane TG, et al. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: A fait accompli? Clin Genitourin Cancer 2018; 16(5): 392-401.
[http://dx.doi.org/10.1016/j.clgc.2018.07.009] [PMID: 30120038]
[45]
Caglar M, Tuncel M, Yildiz E, Karabulut E. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: Comparison with Ga-68 PSMA PET/CT. Ann Nucl Med 2020; 34(12): 932-41.
[http://dx.doi.org/10.1007/s12149-020-01529-9] [PMID: 32975741]
[46]
Rosar F, Neher R, Burgard C, et al. Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC. Cancers 2022; 14(7): 1696.
[http://dx.doi.org/10.3390/cancers14071696] [PMID: 35406467]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy